Collectively, these findings suggest that the activation of FXR-SERCA2-eIF2α axis plays a crucial role in AT-II's capacity to restore normal hepatic ER stress signaling and insulin signaling, thereby combating NAFLD. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.